Metered-dose inhaler budesonide-glycopyrrolate-formoterol (Breztri Aerosphere) was associated with a higher risk of a first moderate or severe COPD exacerbation (HR 1.09, 95% CI 1.04-1.14 ...

The upcoming release of Phase III Fasenra data in COPD in 2025 is expected to solidify AstraZeneca’s position in the market.

Currently more than 20 inhalers are approved for the management of COPD and marketed in North America. About half are single medication inhalers and half are combination medication inhalers. This ...

In a cohort of adults with chronic obstructive pulmonary disease (COPD), receiving fluticasone-umeclidinium-vilanterol was ...

The Hailie Smartinhaler device has also been cleared for use with inhalers ... asthma and COPD under a 510(k) over-the-counter clearance. In a statement, the company said the Breztri approval ...

Triple therapy of an inhaled corticosteroid, long acting β 2-agonist (LABA), and long acting muscarinic antagonist (LAMA) is more effective in reducing the annual rate of exacerbations compared with ...

In patients with chronic obstructive pulmonary disease (COPD), the first year of using single-inhaler triple therapy is associated with slightly more major adverse cardiovascular events (MACE) than ...

Clinicians have been concerned whether patients with COPD can achieve sufficient inspiratory flow rates (PIFR) through DPIs due to the devices internal resistance. Aim To study PIFR through Easyhaler® ...

Introduction Inhaler adherence in Chronic Obstructive Pulmonary Disease (COPD) is a crucial component of disease management with studies reporting relationships with both morbidity and mortality. The ...

There was a notable gap in effectiveness between metered-dose and dry-powder formulations of single-inhaler triple therapy for chronic obstructive pulmonary disease (COPD), according to real-world ...